The Journal of dermatology最新文献

{"title":"A Pediatric Case of Malignant Melanoma Successfully Treated With Adjuvant Nivolumab.","authors":"Kanae Okamoto, Takanobu Kan, Takumi Sakamoto, Daiki Matsubara, Hayato Mizuno, Tetsuzo Ishikawa, Akio Tanaka","doi":"10.1111/1346-8138.70545","DOIUrl":"https://doi.org/10.1111/1346-8138.70545","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Psychological Distress in Vitiligo Requires an Action-Linked Pathway Beyond HADS Classification\".","authors":"Naoki Oiso, Yasutaka Mizoro, Kazumasa Kamei, Masato Hoshi","doi":"10.1111/1346-8138.70533","DOIUrl":"https://doi.org/10.1111/1346-8138.70533","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous Eruption With Epidermal Mitotic Figures Followed by Acute Nonscarring Alopecia During Tisotumab Vedotin Treatment.","authors":"Yusuke Sano, Tetsuya Honda","doi":"10.1111/1346-8138.70543","DOIUrl":"https://doi.org/10.1111/1346-8138.70543","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Satisfaction and Patterns Among Primary Hyperhidrosis Patients.","authors":"Chie Uchida, Tomoko Fujimoto, Naoko Okiyama","doi":"10.1111/1346-8138.70539","DOIUrl":"https://doi.org/10.1111/1346-8138.70539","url":null,"abstract":"<p><p>Primary hyperhidrosis can substantially impair daily activities and psychosocial well-being. This single-center cross-sectional questionnaire study examined treatment use and factors associated with treatment satisfaction among 92 patients with primary hyperhidrosis recruited by treating physicians at a single clinic between 2024 and 2025. Treatment use was analyzed at the patient-treatment level using logistic regression with patient-level clustering. Factors associated with treatment satisfaction were evaluated using generalized estimating equation logistic regression, and sensitivity analyses applied alternative satisfaction thresholds. Patient-reported sweat reduction was the factor most consistently associated with treatment satisfaction. This association remained evident in adjusted models and sensitivity analyses. In contrast, time to treatment effect, hyperhidrosis disease severity scale score, sex, age group, treatment-related adverse events, treatment modality, and affected site showed no statistically significant or consistent associations with satisfaction. Sweat reduction and satisfaction wasn't completely concordant; some observations indicated satisfaction despite poor sweat reduction, whereas dissatisfaction despite favorable sweat reduction was rare. Treatment frequency showed no consistent association with satisfaction, and treatment duration differed only under one strict definition of satisfaction. Although affected site was not independently associated with satisfaction in the regression models, descriptive satisfaction rates varied across body-site and treatment-modality combinations. Patient-reported sweat reduction did not fully explain treatment satisfaction. Treatment benefit should therefore be assessed comprehensively by considering perceived sweat reduction, treatment burden, and broader clinical context.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recognizing Mandibular Hypoplasia, Deafness, Progeroid Features, and Lipodystrophy Syndrome Through Its Cutaneous Manifestations: Distinction From Werner Syndrome.","authors":"Chiaki Yamashiro, Kwesi Teye, Takahiro Hamada, Norito Ishii, Hiroshi Koga","doi":"10.1111/1346-8138.70541","DOIUrl":"https://doi.org/10.1111/1346-8138.70541","url":null,"abstract":"<p><p>Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome (MDPL) is an extremely rare autosomal dominant progeroid disorder caused by pathogenic variants in POLD1. Because MDPL shares many clinical features with Werner syndrome (WS), distinguishing between the two disorders can be challenging. We report a Japanese man with genetically confirmed MDPL caused by the recurrent POLD1 p.Ser605del variant, highlighting its distinctive cutaneous manifestations. The patient exhibited mandibular hypoplasia, limb-predominant lipodystrophy, skin atrophy, painful plantar clavi and calluses, and later developed prominent telangiectasias. Radiographs at the initial presentation revealed multiple extraosseous calcifications in the lower leg, followed by the development of a refractory skin ulcer over the same calcified region. Computed tomography confirmed calcifications within the subcutaneous tissue and skeletal muscle. To our knowledge, soft-tissue calcification and refractory skin ulceration have not previously been reported in MDPL. Although MDPL shares substantial clinical overlap with WS, it can be distinguished by its earlier onset, preserved scalp hair, prominent telangiectasias, sensorineural hearing loss, an absence of cataracts, and a lack of a recognized predisposition to malignancy. This case expands the cutaneous spectrum of MDPL and emphasizes the dermatological clues that facilitate its differentiation from WS.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149208419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tovorafenib-Induced Poliosis.","authors":"Karol Sabas-Ortega, Maria Dolores Mendoza-Cembranos, Antonio Torrelo","doi":"10.1111/1346-8138.70544","DOIUrl":"https://doi.org/10.1111/1346-8138.70544","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149208379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Molecular Epidemiology and Genotype-Phenotype Correlations in Keratinocytic Epidermal Nevus: A Systematic Review.","authors":"Fang Zhang, Zhongtao Li, Deyu Song, Sheng Wang","doi":"10.1111/1346-8138.70535","DOIUrl":"https://doi.org/10.1111/1346-8138.70535","url":null,"abstract":"<p><p>Keratinocytic epidermal nevi (KEN) represent a heterogeneous group of mosaic skin disorders driven by diverse causative genes. This systematic review aimed to delineate the global molecular epidemiology of KEN, establish genotype-phenotype correlations, and define a stratified framework for molecular diagnosis and targeted therapy. We searched PubMed, Embase, Scopus, and Web of Science from inception to May 31, 2026. Data from 141 patients across 77 reports were extracted, and associations were analyzed by histopathological subtype, lesion distribution, and systemic involvement. Generalized KEN was more common than localized forms (55.3% vs. 36.2%). Pathogenic mutations were detected in 79.4% of cases, most frequently in HRAS, KRT10, FGFR3, KRAS, and FGFR2. Non-epidermolytic KEN (n = 94) predominantly harbored RAS/MAPK and receptor tyrosine kinase pathway mutations, whereas epidermolytic KEN (n = 18) was associated with KRT1/2/10 mutations, and inflammatory linear verrucous epidermal nevus (n = 24) displayed heterogeneous alterations. Mutation detection in lesional skin was significantly higher than in peripheral blood (78.3% vs. 27.8%), with generalized forms showing higher peripheral blood positivity than localized forms (41.0% versus 14.0%). HRAS c.34G>A and FGFR3 c.742C>T were predominantly observed in generalized KEN, whereas HRAS c.37G>C, FGFR2 c.755C>G, and EGFR exon 20 insertions were mainly detected in localized disease. Extracutaneous manifestations (27.7% of cases, primarily with KRAS, FGFR3, and HRAS) and parent-to-offspring transmission (15 pedigrees, predominantly involving KRT1/10) more often occurred in generalized KEN. Nine patients received genotype-directed targeted therapies with satisfactory responses. These findings delineate a comprehensive genotype-phenotype landscape of KEN and propose a lesional tissue-based tiered molecular diagnostic strategy incorporating high-depth sequencing for mechanism-driven targeted therapy and genetic counseling. Integrating clinical, histopathological, and molecular data within this framework offers a practical foundation for diagnostic stratification and precision medicine in KEN.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149208366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RNA-Validated Spliceogenic Synonymous TGFB3 Variant in Loeys-Dietz Syndrome Without Vascular Involvement.","authors":"Mirei Yamamoto, Shujiro Hayashi","doi":"10.1111/1346-8138.70540","DOIUrl":"https://doi.org/10.1111/1346-8138.70540","url":null,"abstract":"","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Serum Thymus and Activation-Regulated Chemokine Levels and 1-Year Relapse in Bullous Pemphigoid: A Retrospective Cohort Study.","authors":"Shohei Kitayama, Teruhiko Makino, Yu Matsui, Megumi Mizawa, Tadamichi Shimizu","doi":"10.1111/1346-8138.70542","DOIUrl":"10.1111/1346-8138.70542","url":null,"abstract":"<p><p>Baseline serological markers associated with relapse risk in bullous pemphigoid (BP) remain insufficiently defined. Serum thymus and activation-regulated chemokine (TARC) reflects type 2 inflammation and disease activity in BP, but whether its baseline level is associated with subsequent relapse has not been fully clarified. We retrospectively reviewed 109 Japanese patients with BP treated at Toyama University Hospital between January 2006 and September 2025. The primary endpoint was relapse within 1 year after treatment initiation. Associations between baseline serum TARC levels and time to relapse were evaluated using Cox proportional hazards models. During 1 year of follow-up, 31 patients relapsed and 9 died. Higher serum TARC levels were associated with relapse in univariable analysis (hazard ratio, 1.19 per doubling; 95% confidence interval, 1.02-1.39; p = 0.029). In the primary multivariable Cox model adjusted for age, dementia, total bullous pemphigoid disease area index (BPDAI) score, and anti-BP180NC16A antibody titer, the association was attenuated and was not statistically significant (hazard ratio, 1.16; 95% confidence interval, 0.95-1.42; p = 0.138). The corresponding Fine-Gray analysis yielded a similar result (subdistribution hazard ratio, 1.17; 95% confidence interval, 0.96-1.43; p = 0.120). Among patients without prior systemic glucocorticoid exposure, serum TARC remained associated with relapse in both Cox (hazard ratio, 1.34; 95% confidence interval, 1.03-1.73; p = 0.027) and Fine-Gray analyses (subdistribution hazard ratio, 1.35; 95% confidence interval, 1.03-1.75; p = 0.029). In this subgroup, adding serum TARC to the multivariable model increased the concordance index from 0.582 to 0.653 and improved model fit (likelihood ratio test, p = 0.025). These exploratory findings suggest that baseline serum TARC may provide modest complementary prognostic information when measured before systemic glucocorticoid treatment, although external validation is required.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149198532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Refractory Psoriatic Lesions in Japanese Patients Before and After Switching Biologics.","authors":"Takayo Ando, Koji Kamiya, Megumi Kishimoto, Natsuko Sugihara, Junichi Sugai, Makiko Mieno, Mamitaro Ohtsuki, Mayumi Komine","doi":"10.1111/1346-8138.70532","DOIUrl":"https://doi.org/10.1111/1346-8138.70532","url":null,"abstract":"<p><p>Biologics can improve disease control in patients with psoriasis vulgaris (PsO) and psoriatic arthritis (PsA); however, refractory regions may persist despite biologic therapy. This study aimed to evaluate refractory anatomical regions in patients with PsO and PsA who underwent biologic switching. We retrospectively analyzed 71 biologic-switching episodes from 50 patients treated at Jichi Medical University Hospital between January 1, 2010 and December 31, 2019. Patients who underwent more than one biologic switch contributed multiple switching episodes. Refractory regions were assessed across 13 anatomical regions at the time of biological switching and at the end of the observation period. The lower extremities were the most frequently affected refractory region in both PsO and PsA, followed by the upper extremities in PsO and the scalp in PsA. Overall, the distribution of refractory regions was broadly similar before and after biologic switching. Improvement was defined as complete disappearance of a lesion that had been explicitly documented as present before biologic switching. Regions explicitly documented as lesion-free before switching were classified as non-improved, whereas regions without documentation regarding the presence or absence of a lesion before switching were excluded from the analysis. A logistic generalized linear mixed-effects model with a random intercept for switching episode was used to account for within-episode correlation among anatomical regions. The oral-to-biologic group had higher odds of documented lesion improvement than the biologic-to-biologic group (odds ratio, 2.12; p < 0.001), whereas disease subtype was not significantly associated with documented lesion improvement (PsO vs. PsA: odds ratio, 1.03; p = 0.876). These findings suggest that patients requiring biologic-to-biologic switching may represent a more treatment-refractory population. The lower extremities remained a particularly challenging anatomical region after biologic switching. Further prospective studies are warranted to clarify the factors associated with site-specific treatment response.</p>","PeriodicalId":94236,"journal":{"name":"The Journal of dermatology","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149187180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}